Patents by Inventor Yaping Shen
Yaping Shen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100174101Abstract: The present invention provides a novel multi-step process for the manufacturing Fulvestrant, which is economical and convenient to operate at commercial scale, and requires only simple chromatographic separations after the coupling step of adding the side chain to the 7 position of the steroid.Type: ApplicationFiled: September 24, 2007Publication date: July 8, 2010Applicant: XI'AN LIBAND PHARMACEUTICAL CO., LTD.Inventors: Suoding Cao, Yuanlin Zhou, Yaping Shen, Tao Chen
-
Publication number: 20100168170Abstract: There is provided compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, m, n, q and r have meanings given in the description, and pharmaceutically acceptable derivatives thereof, which compounds are useful in the treatment of diseases and conditions associated with inflammation.Type: ApplicationFiled: March 12, 2008Publication date: July 1, 2010Inventors: Benjamin Pelcman, Christian Krog-Jensen, Yaping Shen, James Gee Kan Yee, Lloyd F. Mackenzie, Yuanlin Zhou, Kang Han, Jeffery R. Raymond
-
Publication number: 20100168167Abstract: There is provided compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, m and n have meanings given in the description, and pharmaceutically acceptable derivatives thereof, which compounds are useful in the treatment of diseases and conditions associated with inflammation.Type: ApplicationFiled: March 12, 2008Publication date: July 1, 2010Inventors: Benjamin Pelcman, Christian Krog-Jensen, Yaping Shen, James Gee Kan Yee, Lloyd F. MacKenzie, Yuanlin Zhou, Kang Han, Jeffery R. Raymond
-
Patent number: 7459479Abstract: The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof.Type: GrantFiled: March 8, 2007Date of Patent: December 2, 2008Assignee: Biolipox ABInventors: Ronald W. Lauener, David L. Burgoyne, Patrick J. Rebstein, Lloyd F. Mackenzie, Yuanlin Zhou, Yaping Shen
-
Publication number: 20080287522Abstract: The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof.Type: ApplicationFiled: July 21, 2008Publication date: November 20, 2008Applicant: BIOLIPOX ABInventors: Ronald W. Lauener, David L. Burgoyne, Patrick J. Rebstein, Lloyd F. Mackenzie, Yuanlin Zhou, Yaping Shen
-
Patent number: 7446129Abstract: The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof.Type: GrantFiled: March 18, 2003Date of Patent: November 4, 2008Assignee: Biolipox ABInventors: Ronald W Lauener, David L Burgoyne, Patrick J Rebstein, Lloyd F Mackenzie, Yuanlin Zhou, Yaping Shen
-
Publication number: 20070208181Abstract: The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof.Type: ApplicationFiled: March 8, 2007Publication date: September 6, 2007Applicant: INFLAZYME PHARMACEUTICALS LTD.Inventors: Ronald Lauener, David Burgoyne, Patrick Rebstein, Lloyd Mackenzie, Yuanlin Zhou, Yaping Shen
-
Publication number: 20070060553Abstract: A compound of the formula and pharmaceutically acceptable salts, solvates, stereoisomers and prodrugs thereof, in isolation or in mixture, wherein, independently at each occurrence: R1 and R2 are selected from hydrogen, oxygen so as to form nitro or oxime, amino, sulfate, and sulfonic acid, and organic groups having 1-30 carbons and optionally containing 1-6 heteroatoms selected from nitrogen, oxygen, phosphorous, silicon, and sulfur, where R1 and R2 may, together with the N to which they are both bonded, form a heterocyclic structure that may be part of an organic group having 1-30 carbons and optionally containing 1-6 heteroatoms selected from nitrogen, oxygen and silicon, and where R1 may be a 2, or 3 atom chain to numeral 2 so that —N—R1— forms part of a fused bicyclic structure to ring A; R3 and R4 are selected from direct bonds to 6 and 7 respectively so as to form carbonyl groups, hydrogen, or a protecting group such that R3 and/or R4 is part of hydroxyl or carbonyl protecting group; numerals 1 thType: ApplicationFiled: July 28, 2006Publication date: March 15, 2007Applicant: Inflazyme Pharmaceuticals Ltd.Inventors: Jeffery Raymond, Claudia Kasserra, Yaping Shen
-
Patent number: 7112580Abstract: A compound of the formula: and pharmaceutically acceptable salts, solvates, stereoisomers and prodrugs thereof, in isolation or in mixture, wherein R groups are as defined by the present specification. The compounds may be formulated into pharmaceutical compositions, and used in the treatment and/or prevention of various conditions, including inflammation, asthma, an allergic disease, chronic obstructive pulmonary disease, atopic dermatitis, solid tumors, AIDS, ischemia, and cardiac arrhythmias.Type: GrantFiled: July 21, 2003Date of Patent: September 26, 2006Assignee: Inflazyme Pharmaceuticals Ltd.Inventors: Jeffery R Raymond, Claudia E Kasserra, Yaping Shen
-
Publication number: 20060211857Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6? and 7? oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6? and 7? oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and ?-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.Type: ApplicationFiled: November 22, 2005Publication date: September 21, 2006Applicants: Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of AlbertaInventors: David Burgoyne, Yaping Shen, John Langlands, Christine Rogers, Joseph Chau, Edward Piers, Hassan Salari
-
Patent number: 7067682Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6? and 7? oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6? and 7? oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and ?-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.Type: GrantFiled: November 6, 2003Date of Patent: June 27, 2006Assignees: Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of AlbertaInventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H L Chau, Edward Piers, Hassan Salari
-
Patent number: 6982329Abstract: Steroids containing a cyclohexene moiety are efficiently oxidized to the corresponding ?,?-unsaturated ketone using copper iodide and t-butyl hydroperoxide. A steroid compound containing the ?,?-unsaturated ketone structure is efficiently converted to the corresponding vicinal diol using a hydroborating reagent followed by oxidative workup, e.g., borane followed by sodium perborate. Benzoyl and substituted benzoyls are superior protecting groups for hydroxyl groups present in the compounds.Type: GrantFiled: December 22, 2003Date of Patent: January 3, 2006Assignee: Inflazyme Pharmaceuticals Ltd.Inventors: David L. Burgoyne, Gueijun Ji, Eugene W. Kelleher, Nicholas D. Paschalides, Kishore Ramachandran, Yaping Shen, Yuanlin Zhou
-
Publication number: 20050215534Abstract: A compound of the formula and pharmaceutically acceptable salts, solvates, stereoisomers and prodrugs thereof, in isolation or in mixture, wherein, independently at each occurrence: R1 and R2 are selected from hydrogen, oxygen so as to form nitro or oxime, amino, sulfate, and sulfonic acid, and organic groups having 1-30 carbons and optionally containing 1-6 heteroatoms selected from nitrogen, oxygen, phosphorous, silicon, and sulfur, where R1 and R2 may, together with the N to which they are both bonded, form a heterocyclic structure that may be part of an organic group having 1-30 carbons and optionally containing 1-6 heteroatoms selected from nitrogen, oxygen and silicon, and where R1 may be a 2, or 3 atom chain to numeral 2 so that —N—R1— forms part of a fused bicyclic structure to ring A; R3 and R4 are selected from direct bonds to 6 and 7 respectively so as to form carbonyl groups, hydrogen, or a protecting group such that R3 and/or R4 is part of hydroxyl or carbonyl protecting group; numerals 1 thType: ApplicationFiled: July 21, 2003Publication date: September 29, 2005Applicant: Inflazyme Pharmaceuticals Ltd.Inventors: Jeffery Raymond, Claudia Kasserra, Yaping Shen
-
Patent number: 6949533Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6? and 7? oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6? and 7? oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and ?-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.Type: GrantFiled: November 6, 2003Date of Patent: September 27, 2005Assignees: Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of AlbertaInventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.-L. Chau, Edward Piers, Hassan Salari
-
Publication number: 20040266744Abstract: Steroids containing a cyclohexene moiety are efficiently oxidized to the corresponding &agr;, &bgr;-unsaturated ketone using copper iodide and t-butyl hydroperoxide. A steroid compound containing the &agr;, &bgr;-unsaturated ketone structure is efficiently converted to the corresponding vicinal diol using a hydroborating reagent followed by oxidative workup, e.g., borane followed by sodium perborate. Benzoyl and substituted benzoyls are superior protecting groups for hydroxyl groups present in the compounds.Type: ApplicationFiled: July 15, 2004Publication date: December 30, 2004Inventors: David L Burgoyne, Yaping Shen, Gueijun Ji, Yuanlin Zhou, Kishore D. Ramachandran, Nicholas D. Paschalides, Eugene W. Kelleher
-
Publication number: 20040162425Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6&agr; and 7&bgr; oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6&agr; and 7&bgr; oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and &dgr;-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.Type: ApplicationFiled: November 6, 2003Publication date: August 19, 2004Applicants: Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of AlbertaInventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.-L. Chau, Edward Piers, Hassan Salari
-
Publication number: 20040157814Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6&agr; and 7&bgr; oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6&agr; and 7&bgr; oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and &dgr;-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.Type: ApplicationFiled: November 6, 2003Publication date: August 12, 2004Applicants: Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of AlbertaInventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.L. Chau, Edward Piers, Hassan Salari
-
Patent number: 6770658Abstract: &ggr;-Phenyl-substituted &Dgr;-lactams are disclosed. They may be formulated into pharmaceutical compositions, and/or used in the treatment or prevention of inflammation or other conditions or disease states.Type: GrantFiled: October 1, 2002Date of Patent: August 3, 2004Assignee: Inflazyme Pharmaceuticals Ltd.Inventors: Yaping Shen, David L. Burgoyne, Ronald W. Lauener, Yuanlin Zhou, Patrick J. Rebstein, Samuel D. M. Abraham
-
Publication number: 20040138486Abstract: Steroids containing a cyclohexene moiety are efficiently oxidized to the corresponding &agr;,&bgr;-unsaturated ketone using copper iodide and t-butyl hydroperoxide. A steroid compound containing the &agr;,&bgr;-unsaturated ketone structure is efficiently converted to the corresponding vicinal diol using a hydroborating reagent followed by oxidative workup, e.g., borane followed by sodium perborate. Benzoyl and substituted benzoyls are superior protecting groups for hydroxyl groups present in the compounds.Type: ApplicationFiled: December 22, 2003Publication date: July 15, 2004Applicant: Inflazyme Pharmaceuticals Ltd.Inventors: David L. Burgoyne, Gueijun Ji, Eugene W. Kelleher, Nicholas D. Paschalides, Kishore Ramachandran, Yaping Shen, Yuanlin Zhou
-
Publication number: 20040138186Abstract: A compound of the formula 1Type: ApplicationFiled: July 21, 2003Publication date: July 15, 2004Applicant: Inflazyme Pharmaceuticals Ltd.Inventors: Jeffery R. Raymond, Claudia E. Kasserra, Yaping Shen